More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$17.87B
EPS
-4.41
P/E ratio
--
Price to sales
18.07
Dividend yield
--
Beta
0.397832
Previous close
$271.73
Today's open
$270.06
Day's range
$260.63 - $271.71
52 week range
$188.08 - $282.15
show more
CEO
Jan Møller Mikkelsen
Employees
1189
Headquarters
Hellerup,
Exchange
Nasdaq Global Select
Shares outstanding
65884096
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Ascendis Pharma A/S (ASND) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Ascendis Pharma A/S (ASND) Jefferies Global Healthcare Conference 2026 November 17, 2026 6:30 AM EST Company Participants Jan Mikkelsen - President, CEO, Member of Executive Board & Executive Director Scott Smith - CFO, Executive VP & Member of Executive Board Conference Call Participants Faisal Khurshid - Jefferies LLC, Research Division Presentation Faisal Khurshid Jefferies LLC, Research Division All right. Good morning, everyone.
Seeking Alpha • Nov 17, 2026

Ascendis Pharma A/S Q3 Earnings Call Highlights
Ascendis Pharma A/S NASDAQ: ASND reported third-quarter product revenue of EUR 366 million, up 89% from a year earlier, as sales of hypoparathyroidism treatment YORVIPATH and recently launched achondroplasia drug YUVIWEL grew.
MarketBeat • Nov 12, 2026

Ascendis Pharma A/S (ASND) Q3 2026 Earnings Call Transcript
Ascendis Pharma A/S (ASND) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 12, 2026

Ascendis Pharma Reports Third Quarter 2026 Financial Results
Q3 2026 product revenue of €366 million (+89% Y/Y), comprising €291 million for YORVIPATH ® , €59 million for SKYTROFA ® , and €16 million for YUVIWEL ® Received positive CHMP and COMP opinions recommending EU marketing authorization and maintenance of orphan medicinal product designation for TransCon ® CNP Final EC decision for TransCon CNP expected in Q4 2026; first EU launch planned in Germany in Q1 2027 Presented Week 52 sentinel cohort data in infants with achondroplasia aged 0 to
GlobeNewsWire • Nov 12, 2026

Ascendis Pharma to Participate in the Jefferies London Healthcare Conference
COPENHAGEN, Denmark, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 17, 2026, at 11:30 a.m. Greenwich Mean Time (GMT) / 6:30 a.m. Eastern Time / 3:30 a.m. Pacific Time in London, United Kingdom.
GlobeNewsWire • Nov 10, 2026

Once-Weekly TransCon® CNP (Navepegritide) to Receive 10 Years of Market Exclusivity Upon Approval in the European Union
– Final European Commission decision expected during Q4 2026 COPENHAGEN, Denmark, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending maintenance of orphan medicinal product designation for once-weekly TransCon CNP (navepegritide) as a treatment for achondroplasia in children. The designation would provide Ascendis benefits that include 10 years of orphan market exclusivity upon final adoption of the COMP opinion by the European Commission (EC).
GlobeNewsWire • Nov 6, 2026

Ascendis to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026
COPENHAGEN, Denmark, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it plans to report third quarter 2026 financial results and provide a business update on Thursday, November 12, 2026, before the open of the U.S. financial markets. Ascendis Pharma also plans to host a conference call and live webcast at 8:00 a.m. Eastern Time (ET) that day to discuss its third quarter 2026 financial results and business update.
GlobeNewsWire • Nov 5, 2026

TransCon® PTH (Palopegteriparatide) Demonstrates Sustained, Clinically Meaningful Improvements in Kidney Function in Adults with Hypoparathyroidism Treated Up to 5 Years
COPENHAGEN, Denmark, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data demonstrating early, sustained, and clinically meaningful improvements in kidney function in adults with hypoparathyroidism treated with TransCon® PTH (palopegteriparatide) for up to 5 years in the Company's Phase 2 PaTH Forward and Phase 3 PaTHway trials. Results from the pooled analysis were shared in a poster presented by nephrologist Elvira Gosmanova, M.D.
GlobeNewsWire • Oct 26, 2026

Once-Weekly TransCon® CNP (Navepegritide) Receives Positive CHMP Opinion for the Treatment of Achondroplasia in Children
COPENHAGEN, Denmark, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization for once-weekly TransCon CNP (navepegritide) in the European Union for the treatment of achondroplasia in children two years of age and older whose epiphyses are not closed. The final European Commission (EC) decision on Ascendis Pharma's Marketing Authorisation Application (MAA) is expected during Q4 2026.
GlobeNewsWire • Oct 16, 2026

FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing
BBIO wins FDA priority review for infigratinib, potentially making it the first approved oral therapy for achondroplasia.
Zacks Investment Research • Oct 7, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Ascendis Pharma A/S commission-free¹. Build wealth for the long term using automated trading and transfers.